Dogwood Therapeutics (DWTX) Current Assets (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Current Assets of $15.0 million for Q1 2026, down 21.71% year-over-year from $19.2 million in Q1 2025, and up 77.96% quarter-over-quarter from $8.4 million in Q4 2025.
Dogwood Therapeutics (DWTX) Current Assets (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Current Assets for 7 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 21.71% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (down 21.71% YoY), while the FY2025 annual figure was $8.4 million, down 49.04% from the prior year.
- Current Assets rose to $15.0 million in Q1 2026 per DWTX's latest filing, from $8.4 million in the prior quarter.
- Across five years, Current Assets topped out at $19.2 million in Q1 2025 and bottomed at $2.3 million in Q3 2024.
- Historically, Current Assets has averaged $9.2 million across 5 years, with a median of $8.4 million in 2025.
- Annual changes were most pronounced in 2022 — Current Assets tumbled 61.96% — and 2025, when it jumped 494.3%.
- Dogwood Therapeutics' Current Assets stood at $8.4 million in 2022, then plunged by 50.23% to $4.2 million in 2023, then surged by 297.18% to $16.5 million in 2024, then plunged by 49.04% to $8.4 million in 2025, then jumped by 77.96% to $15.0 million in 2026.
- Business Quant data shows DWTX's Current Assets at $15.0 million in Q1 2026, $8.4 million in Q4 2025, and $11.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 11.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.00 Mn |
| Dec 31, 2025 | 8.43 Mn |
| Sep 30, 2025 | 11.66 Mn |
| Jun 30, 2025 | 14.70 Mn |
| Mar 31, 2025 | 19.16 Mn |
| Dec 31, 2024 | 16.54 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 3.64 Mn |
| Mar 31, 2024 | 3.22 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 5.25 Mn |
| Jun 30, 2023 | 5.21 Mn |
| Mar 31, 2023 | 6.52 Mn |
| Dec 31, 2022 | 8.37 Mn |
| Sep 30, 2022 | 10.86 Mn |
| Jun 30, 2022 | 9.04 Mn |
| Mar 31, 2022 | 12.55 Mn |
| Dec 31, 2021 | 15.78 Mn |
| Sep 30, 2021 | 20.11 Mn |
| Jun 30, 2021 | 23.76 Mn |